Patented aptamers for C-reactive protein detection: A review about their use in clinical diagnostics

Recent Patents on DNA and Gene Sequences

Volumn 7, Issue 3, 2013, Pages 195-206

  Miramontes Espino, María Viviana ^a   Romero Prado, Marina María de Jesús ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Aptamers; Atherosclerosis; C reactive protein; Cardiovascular risk; CRP polymorphisms; Epitope; High sensitivity CRP; Inflammation; Monomeric CRP; Native CRP; Oligopeptide; Prothrombotic state; Single Nucleotide Polymorphism (SNP); Systematic evolution of ligands by exponential enrichment (SELEX); Vascular endothelium

Indexed keywords

APTAMER; C REACTIVE PROTEIN; CD32 ANTIGEN; CD40 ANTIGEN; CD64 ANTIGEN; COMPLEMENT COMPONENT C1Q; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE P38; OXIDIZED LOW DENSITY LIPOPROTEIN; PROSTACYCLIN; SERUM AMYLOID A; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; SYNAPSIN I; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AMINO ACID SEQUENCE; APPLIED RESEARCH; ARTICLE; BASIC RESEARCH; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; GENETIC ASSOCIATION; GENETICS; HEART INFARCTION; HUMAN; INFLAMMATION; LABORATORY DIAGNOSIS; MOLECULAR MECHANICS; MONOCYTE; NEOPLASM; OBESITY; PATENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUDDEN CARDIAC DEATH;

APTAMERS, NUCLEOTIDE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; PATENTS AS TOPIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING;

EID: 84894035933     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221560703140204122543     Document Type: Article

References (82)

1. Kraus VB, Jordan JM. Serum C-Reactive Protein (CRP), Target for Therapy or Trouble?. Biomarker Insights 2006; 1: 77-80.
2. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004; 274: 48487-90.
3. Nicholson JP, Wolmarans MR, and Park GR. The Role of Albumin in Critical Illness. Br J Anaesth 2000; 85: 599-610.
4. Póvoa P, Almeida E, Moreira P, et al. C-reactive protein as an indicator of sepsis. Intens Care Med 1998; 24: 1052-56.
5. Lobo SMA, Lobo FRM, Peres Bota D, et al. C-Reactive Protein Levels Correlate With Mortality and Organ Failure in Critically Ill Patients. Chest 2003; 123: 2043-49.
6. Póvoa P. C-reactive protein: a valuable marker of sepsis. Intens Care Med 2002; 28: 235-43.
7. Kushner I, Samols D, Magrey M. A Unifying Biologic Explanation for "High-Sensitivity" C-Reactive Protein and "low-grade" Inflammation. Arthritis Care Res 2010; 62: 442-46.
8. Rifai N, Ridker PM. Population Distributions of C-Reactive Protein in Apparently Healthy Men and Women in the United States: Implication for Clinical Interpretation. Clinical Chemistry 2003; 49 (4): 666-669.
9. Reeves G. C-reactive protein. Australian Prescriber 2007; 30: 74-76.
10. Brull DJ, Serrano N, Zito F, et al. Human CRP Gene Polymorphism Influences CRP levels: Implications for the Prediction and Pathogenesis of Coronary Heart Disease. Arterioscler Thromb Vasc Biol 2003; 23: 2063-69.
11. Gaitonde S, Samols D, Kushner I. C-Reactive Protein and Systemic Lupus Erythematous. Arthritis CareRes 2008; 59: 1814-20.
12. Hage FG, Szalai AJ. C-Reactive Protein Gene Polymorphisms, Creactive Protein Blood Levels, and Cardiovascular Disease Risk. J Am Coll Cardiol 2007; 50:1115-22.
13. Buckley DI, Fu R, Freeman M, Rogers K, and Helfand M. C. Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analysis for U.S. Preventive Services Task Force. Ann Intern Med 2009; 151 (7): 483-495.
14. Heusch G, Schulz R. C-Reactive Protein just a Biomarker of Inflammation or a Pathophysiological player in myocardial function and morphology. Am Heart Assoc 2011; 57: 151-153.
15. Ridker PM. Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention. Circulation 2003; 107: 363-69.
16. Osman R, L'Allier PL, Eigharib N, Tardif J-C. Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc Health Risk Manag. 2006; 2 (3): 221-37.
17. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Eng J Med 2000; 342: 836-43.
18. Odrowaz-Sypniewska G. Markers of pro-inflammatory and prothrombotic state in the diagnosis of metabolic syndrome. Advances in Medical Sciences 2007; 52: 246-250.
19. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
20. Fröhlich M, Imhof A, Berg G, et al. Association Between CReactive Protein and Features of the Metabolic Syndrome. Diabetes Care 2000; 23: 1835-1839.
21. Greenfield JR, Samaras K, Jenkins AB, et al. Obesity is an Important Determinant of Baseline Serum C-Reactive Protein Concentration in Monozygotic Twins, Independent of Genetic Influences. Circulation 2004; 109: 3022-3028.
22. Devaraj S, Goyal R, Jialal I. Inflammation, Oxidative Stress, and the Metabolic Syndrome. Diabetes Pathophysiology 2008; 32-37.
23. Visser M, Bouter LM, Wener MH, and Harris TB. Elevated CReactive Protein Levels in Overweight and Obese Adults. JAMA 1999; 282 (22): 2131-2135.
24. Den Engelsen C, Koekkoek PS, Gorter KJ, Van Den Donk M, Salomé PL, and Rutten GE. High-sensivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a crosssectional analysis. Cardiovascular Diabetology 2012; 11:25.
25. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer. J Clin Oncol 2009; 27: 2217-24.
26. Khreiss T, József L, Potempa LA, Filep JG. Conformational Rearrangement in C-Reactive Protein is Required for Proinflammatory Actions on Human Endothelial Cells. Circulation 2004; 109: 2016-2022.
27. Pasceri V, Willerson JT, and Yeh ETH. Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells. Circulation 2000; 102: 2165-2168.
28. Khreiss T, József L, Potempa LA, and Filep JG. Loss of Pentameric Symmetry in C-Reactive Protein Induces Interleukin-8 Secretion Through Peroxynitrite Signaling in Human Neutrophils. Circ Res 2005; 97: 690-697.
29. Devaraj S, Davis B, Simon SI, Jialal I. CRP promotes monocyteendothelial cell adhesion via Fcy receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol 2006; 291: H1170-H1176.
30. Bíró A, Rovó Z, Papp D, et al. Studies on the interactions between C-reactive protein and complements proteins. Immunology 2007; 121 (19): 40-50.
31. Pearson TA, Mensah GA, Alexander W, et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
32. Torzewski M, Rist C, Mortensen RF, et al. C-Reactive Protein in the Arterial Intima: Role of C-Reactive Protein Receptor-Dependent Monocyte Recruitment in Atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-2099.
33. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-Reactive Protein and Complement Components in Atherosclerotic Plaques. Am J Pathol 2001; 158 (3): 1039-1051.
34. Burke AP, Tracy RP, Kolodgie F, et al. Circulation 2002; 105: 2019-2023.
35. Montecucco F, Mach F. New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clinical Interventions in Aging 2002; 3 (2): 341-349.
36. Cirillo P, Golino P, Calabrò P, Calì G, Ragni M. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovascular Research 2005; 68: 47-55.
37. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardivoascular Research 2003; 58: 186-195.
38. Libby P, Ridker PM, Hansson GK. Inflammation in Atherosclerosis. J Am Coll Cardiol 2009; 54: 2129-38.
39. Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ESG, Kastelein JJP. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J 2010; 31: 2087-95.
40. Shih HH, Zhang S, Cao W, et al. CRP is a novel ligand for the oxidized LDL receptor LOX-1. Am J Physiol Heart Circ Physiol 2009; 296: H1643-H1650.
41. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. PNAS 2002; 99 (20): 13043-13048.
42. Li L, Roumeliotis N, Sawamura T, Renier G. C-Reactive Protein Enhances LOX-1 Expression in Human Aortic Endothelial Cells: Relevance of LOX-1 to C-Reactive Protein-Induced Endothelial Dysfunction. Circ Res 2004; 95: 877-883.
43. Iwai-Kanai E, Hasegawa K, Sawamura T, et al. Activation of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Induces Apoptosis in Cultured Neonatal Rat Cardiac Myocytes. Circulation 2001; 104: 2948-2954.
44. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders. Cardiovascular Research 2006; 69: 36-45.
45. Fujita Y, Yamaguchi S, Kakino A, Iwamoto S, Yoshimoto R, Sawamura T. Lectin-like Oxidized LDL Receptor 1 is Involved in CRP-Mediated Complement Activation. Clinical Chemistry 2011; 57 (10): 1398-1405.
46. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells. Circulation 2002; 106: 1439-1441.
47. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-Reactive Protein Decreases Endothelial Nitric Oxide Synthase Activity via Uncoupling. J Mol Cell Cardiol 2007; 43 (6): 780-791.
48. Valleggi S, Devaraj S, Dasu MR, Jialal I. C-Reactive Protein Adversely Alters the Protein-Protein Interaction of the Endothelial Isoform of Nitric Oxide Synthase. Clinical Chemistry 2010; 56 (8): 1345-1348.
49. Nakagomi A, Freedman SB, Geczy CL. Interferon-y and Lipopolysaccharide Potentiate Monocyte Tissue Factor Induction by CReactive Protein: Relationship With Age, Sex, and Hormone Replacement Treatment. Circulation 2000; 101: 1785-1791.
50. Toschi V, Gallo R, Lettino M, et al. Tissue Factor Modulates the Thrombogenicity of Human Atherosclerotic Plaques. Circulation 1997; 95 (3): 594-9.
51. Ardissino D, Merlini PA, Bauer KA, et al. Thrombogenic potential of human coronary atherosclerotic plaques. Blood 2001; 98: 2726-2729.
52. Yaron G, Brill A, Dashevsky O, et al. C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol 2006; 134 (4): 426-31.
53. Danenberg HD, Kantak N, Grad E, Swaminathan RV, Lotan C, and Edelman ER. C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy. Eur J Haematol 2007; 78 (3): 246-52.
54. Devaraj S, Yan Xu D, and Jialal I. C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis. Circulation 2003; 107: 398-404.
55. Bisoendial RJ, Kastelein JJP, Levels JHM, et al. Activation of Inflammation and Coagulation after Infusion of C-Reactive Protein in Humans. Circ Res 2005; 96: 714-716.
56. Singh U, Devaraj S, Jialal I. C-Reactive Protein Decreases Tissue Plasminogen Activator Activity in Human Aortic Endothelial Cells: Evidence that C-Reactive Protein is a Procoagulant. Arterioscler Thromb Vasc Biol 2005; 25: 2216-2221.
57. Nabata A, Kuroki M, Ueba H, et al. C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: Implications for the destabilization of atherosclerotic plaque. Atherosclerosis 2008; 196: 129-135.
58. Wang CH, Li SH, Weisel RD, et al. C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle. Circulation 2003; 107: 1783-1790
59. Lange LA, Carlson CS, Hindorff LA, et al. Association of Polymorphisms in the CRP Gene With Circulating C-Reactive Protein Levels and Cardiovascular Events. Am Med Assoc. 2006; 296:2703-2709.
60. Szalai AJ, Alarcón GS, Calvo-Alén J, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology 2005; 44 (7): 864-8
61. Crawford DC, Sanders CL, Qin MX, et al. Genetic Variation Is Associated With C-Reactive Protein Levels in the Third National Health and Nutrition Examination Survey. Am Heart Assoc 2006; 114:2458-2465.
62. Russell AI, Graham DSC, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genetics 2004; 13: 137-147.
63. Mendoza-Carrera F, Ramirez-Lopez G, Ayala-Martinez NA et al. Influence of CRP, IL6, and TNFA Gene Polymorphisms on Circulating Levels of C-Reactive Protein in Mexican Adolescents. Arch of Med Res 2010; 41:472-477.
64. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE. C-Reactive Protein and the Risk of Cancer: A Mendelian Randomized Study. J Natl Cancer Inst 2010; 102: 202-206.
65. Ridker PM. High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. Circulation 2001; 103: 1813-1818.
66. Roberts WL, Moulton L, Law TC, et al. Evaluation of Nine Automated High-Sensitivity C-Reactive Protein Methods: Implications for Clinical and Epidemiological Applications. Part 2. Clinical Chemistry 2001; 47 (3): 418-425.
67. Nestor JJ, Ho TH, Eppstein DA, Felgner PL, Barna BP, Deodhar SD. C-reactive protein fragment with immunomodulatory activity. US 1998/5783179, 1998.
68. Yinghe HU, Wenze NIU, Jiang N. Protein detection by aptamers. WO 2007/117444A3, 2007.
69. Davydova AS, Vorobjeva MA, Venyaminova AG. Escort Aptamers: New Tools for theTargeted Delivery of Therapeutics into Cells. Acta naturae 2011; 3 (4) 1-29.
70. Stoltenburg R, Reinemann C, Strehlitz B. SELEX-A® evolutionary method to generate high-affinity nucleic acid ligands. Biomol Engineering 2007; 24:381-403.
71. Yang Y, Yang D, Schluesener HJ, Zhang Z. Advances in SELEX and application of aptamers in the central nervous system. Biomol Engineering 2007; 24:583-592.
72. Dua P, Kim S, Lee D-k. Nucleic acid aptamers targeting cellsurface proteins. Methods 2011; 54:215-225.
73. Lee G-W, Shiesh S-C, Huang C-J, Lin H-I. Aptamer and detection method for C-reactive protein. US 2011/03188465 A1, 2011.
74. Kim SD, Ryu JS, Yi H-K, Kim S-C, Zhang B-T. Construction of C-reactive protein-binding aptamer as a module of the DNA computing system for diagnosing cardiovascular diseases. In: Preliminary proceedings of the tenth international meeting on DNA computing 2004:334-343.
75. Huang CJ, Lin HI, Shiesh SC, Lee GB. Integrated microfluidic system for rapid screening of CRP aptamers utilizing systematic evolution of ligands by exponential enrichment (SELEX). Biosens Bioelectron 2010, 25(7): 1761-1766.
76. Stoltenberg R, Reinemann C, Strehlitz B. FluMag-SELEX as an advantageous method for DNA aptamer selection. Anal Bioanal Chem 2005; 383(1): 83-91.
77. Heyduk T, Heyduk E. Methods for the selection of aptamers. US2009/0202990 A1, 2009.
78. Heyduk T, Heyduk E, Knoll E. Biosensors for detecting macromolecules and other analytes. US 2011/0091893 A1, 2011.
79. Wang MS, Black JC, Knowles MK, Reed SM. C-reactive protein (CRP) aptamers binds to monomeric but not pentameric form of CRP. Anal Bioanal Chem 2011; 401:1309-18.
80. Mann D, Reinemann C, Stoltenberg R, Stehlitz B. In vitro selection of DNA aptamers binding ethanolamine. Biochem Biophys Res Commun 2005; 338: 1928-34.
81. Chapman JA, Beckey C. Pegaptanib: a novel approach to ocular neovascularization. Ann Pharmacother 2006; 40: 1322-26.
82. Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 123-32.